Amgen Inc. — 2022 Form 10-K Summary
Business context and reporting period
Amgen is a global biotechnology company operating in one segment, human therapeutics. This annual filing covers the fiscal year ended December 31, 2022; it does not provide a standalone fourth-quarter financial summary. Unless noted otherwise, amounts are U.S. dollars.
Financial performance and liquidity
| Metric | 2022 | 2021 | Change |
|---|---|---|---|
| Total revenues | $26.323 billion | $25.979 billion | +1% |
| Product sales | $24.801 billion | $24.297 billion | +2% |
| Operating income | $9.566 billion | $7.639 billion | +25% |
| Net income | $6.552 billion | $5.893 billion | +11% |
| Diluted EPS | $12.11 | $10.28 | +18% |
| Operating cash flow | $9.721 billion | $9.261 billion | +5% |
- Operating margin was approximately 36.4%, up from 29.4%; net margin was approximately 24.9%, up from 22.7%.
- Operating expenses fell 9% to $16.757 billion. The 2021 comparison included $1.505 billion of acquired in-process R&D expense for Five Prime and a $400 million upfront licensing payment to Kyowa Kirin.
- Cost of sales was $6.406 billion, or 24.3% of revenue, versus $6.454 billion, or 24.8%, in 2021. R&D expense decreased 8% to $4.434 billion.
- Cash, cash equivalents and marketable securities totaled $9.305 billion at year-end. Total debt carrying value was $38.945 billion, versus $33.309 billion a year earlier; stockholders’ equity fell to $3.661 billion from $6.700 billion.
- Operating cash flow less capital expenditures was approximately $8.785 billion ($9.721 billion less $936 million). Capital expenditures were $936 million; management estimated about $925 million for 2023.
- The company paid $4.196 billion in dividends and $6.360 billion for share repurchases in 2022. It issued $7.0 billion of debt and extinguished $297 million.
- Current assets were $22.186 billion and current liabilities $15.687 billion at year-end. The company reported investment-grade senior-note ratings and compliance with applicable debt covenants.
Material changes versus the prior comparable period
- Product sales growth reflected volume gains in products including Prolia, Nplate, Repatha, KYPROLIS and EVENITY, partly offset by lower net prices and unfavorable foreign exchange.
- Neulasta sales declined 35% to $1.126 billion amid biosimilar competition; ENBREL sales declined 8% to $4.117 billion. EVENITY grew 48% to $787 million and Nplate grew 27% to $1.307 billion.
- Other revenues declined 10% to $1.522 billion, mainly due to lower COVID-19 antibody material and licensing-related revenues.
- Net income remained below 2020’s $7.264 billion. 2022 results included $814 million of other non-operating expense, compared with $259 million of other income in 2021, reflecting investment-related losses, including on BeiGene and limited partnerships.
- Amgen acquired ChemoCentryx in October for approximately $3.9 billion, adding TAVNEOS, and recorded a $567 million loss on the November sale of Gensenta, primarily from reclassifying accumulated foreign currency translation losses.
Outlook, management commentary and key risks
- Management expects portfolio-wide net selling prices to continue declining in 2023, driven by competition, and anticipates continued foreign-exchange volatility. The filing text does not provide clear numerical 2023 revenue or EPS guidance.
- Amgen agreed to acquire Horizon for $116.50 per share in cash, representing approximately $27.8 billion in equity value. It arranged up to $28.5 billion in bridge and term-loan facilities, none drawn at year-end; the transaction remained subject to regulatory and other closing conditions. The FTC issued a Second Request in January 2023, extending its review period.
- The pipeline advanced to 18 Phase 3 programs as of January 31, 2023, up from 13 a year earlier. Management highlighted clinical and regulatory uncertainty, including the need for confirmatory evidence for LUMAKRAS’s accelerated approval.
- Major risks include biosimilar and generic competition, payer and pricing pressure, implementation of the Inflation Reduction Act, product and pipeline safety or efficacy, patent disputes, manufacturing and supplier concentration, cybersecurity, and the effects of COVID-19 and macroeconomic conditions.
- Amgen is contesting IRS transfer-pricing notices in Tax Court. The notices seek approximately $3.6 billion in additional federal tax for 2010–2012 and $5.1 billion plus approximately $2.0 billion in asserted penalties for 2013–2015, before potential offsets for previously accrued repatriation tax. The company disputes the IRS positions; final resolution is not expected within 12 months.
- The Inflation Reduction Act introduces Medicare drug-price negotiation beginning in 2026 and inflation-based rebates, among other changes. Amgen says the eventual effect on its sales remains uncertain.
- Auditor Ernst & Young issued unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- How much reported earnings growth came from lower prior-year acquisition and licensing charges, versus durable operating improvement; also monitor investment-related losses and the Gensenta divestiture impact.
- Whether pricing pressure and biosimilar competition accelerate, particularly for Neulasta and ENBREL, and whether volume growth offsets lower net prices.
- The FTC and other regulatory outcomes, financing terms and leverage implications of the proposed Horizon acquisition.
- The status and potential financial exposure of the IRS disputes, including accrued liabilities, interest and possible offsets.
- Progress of key Phase 3 programs and confirmatory studies, and whether clinical results translate into approvals, reimbursement and commercial sales.
- Product-sales deductions were 51% of gross product sales in 2022, up from 47% in 2021; verify the assumptions and trends behind the $5.986 billion year-end accrual.